Laekna (2105.HK) today announced that the company will present an internally discovered preclinical candidate at the 2024 San Antonio Breast Cancer Symposium (SABCS) on December 13, 2024. The ...
LAE002 (afuresertib) is a potent AKT inhibitor that inhibits all three AKT isoforms (AKT1, AKT2 and AKT3) as well as one of the only two AKT inhibitors in late-stage development for breast and ...
A recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 ... A mammalian cell-based assay for screening inhibitors of RNA cleavage. Methods in Molecular Biology, 540:335 (2009). Link ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback